CoreCap Advisors’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$33.7K Hold
136
﹤0.01% 1591
2026
Q1
$27.3K Hold
136
﹤0.01% 1548
2025
Q4
$28.1K Sell
136
-55
-29% -$11K ﹤0.01% 1551
2025
Q3
$34.2K Sell
191
-37
-16% -$6.3K ﹤0.01% 1465
2025
Q2
$36.8K Hold
228
﹤0.01% 1369
2025
Q1
$38.8K Sell
228
-101
-31% -$17.5K ﹤0.01% 1275
2024
Q4
$54.6K Sell
329
-25
-7% -$4.27K ﹤0.01% 1150
2024
Q3
$60.9K Buy
+354
New +$58.6K ﹤0.01% 1114
2024
Q2
Sell
-489
Closed -$75.2K 1905
2024
Q1
$75.2K Buy
+489
New +$74.6K ﹤0.01% 963
2022
Q4
$124K Buy
+804
New +$119K 0.01% 657
2022
Q3
Sell
-919
Closed -$125K 1028
2022
Q2
$125K Buy
+919
New +$127K 0.01% 622
2022
Q1
Sell
-874
Closed -$142K 1033
2021
Q4
$142K Buy
+874
New +$141K 0.01% 634

Other funds holding FBT

CoreCap Advisors's FBT Position: Q2 2026 in Review

CoreCap Advisors held its First Trust NYSE Arca Biotechnology Index Fund (FBT) position steady in Q2 2026 at 136 shares worth $33.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1591.

CoreCap Advisors first reported a position in FBT in Q4 2021 and has held it in 12 quarters since. The position peaked at $142K in Q4 2021. 66 funds tracked by Wall St. Rank hold FBT as of Q2 2026.

  • CoreCap Advisors held 136 shares of First Trust NYSE Arca Biotechnology Index Fund worth $33.7K as of Q2 2026.
  • CoreCap Advisors left its First Trust NYSE Arca Biotechnology Index Fund share count unchanged in Q2 2026.
  • First Trust NYSE Arca Biotechnology Index Fund made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1591 holding.
  • CoreCap Advisors first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2021 and has held it in 12 quarters since.
  • CoreCap Advisors's First Trust NYSE Arca Biotechnology Index Fund position peaked at $142K in Q4 2021.
  • 66 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.